Home / Health / New Weekly Insulin Shot Cuts 365 Injections to 52
New Weekly Insulin Shot Cuts 365 Injections to 52
16 Aug
Summary
- Weekly insulin injection approved for Type 2 diabetes patients.
- Reduces daily shots to 52 per year, easing patient burden.
- Potential risks include hypoglycemia and insurance coverage uncertainties.
A groundbreaking weekly insulin injection, Awiqli, is now available for Type 2 diabetes patients, offering a significant reduction from 365 daily shots to 52 annually. This innovation by Novo Nordisk aims to simplify treatment and improve patient convenience.
Despite the appeal of fewer injections, medical professionals advise caution. The primary concern is the risk of hypoglycemia, or dangerously low blood sugar, a known side effect noted in clinical trials. Experts suggest this new insulin may serve a niche population, such as the elderly or those with cognitive difficulties.
Daily glucose monitoring remains crucial to determine the appropriate weekly dosage and manage blood sugar levels effectively. While the list price for a single multi-dose pen is $99, Novo Nordisk offers a monthly supply for $35 with Medicare Part D or commercial insurance, and $55 for the uninsured.
Insurance coverage details are still emerging, with potential for prior authorization requirements. This makes access a key factor to watch as Awiqli becomes more widely available.
